Pharmafile Logo
Pharmafocus logo
Advanced Search

bone cancer

Showing 2 posts of 2 posts found.

bonecells

OS Therapies advances regulatory pathway for bone cancer therapy

August 11, 2025
Medical Communications, Research and Development European Medicines Agency’, Medicines and Healthcare products Regulatory Agency, OS Therapies, Oncology, Orthopaedics, US Food and Drug Administration’, bone cancer, osteosarcoma

OS Therapies has announced significant progress in its regulatory strategy for OST-HER2, its lead immunotherapy candidate for preventing or delaying …

News

NICE rejects Takeda cancer drug over price concerns

July 12, 2010
Sales and Marketing Cancer, Mepact, NICE, Takeda, bone cancer

UK cost-effectiveness watchdog NICE has rejected Takeda’s orphan bone cancer drug Mepact due to concerns over price. In its draft …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025